Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio?

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Thrombosis and Thrombolysis

• Publication date

  2009-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11239-008-0219-9PMID 18392557
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.

  2007influential reference
• Evaluation of Genetic Factors for Warfarin Dose Prediction

  2007cited by this paper
• Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence‐based data?

  2006cited by this paper
• Early detection of patients with a poor response to vitamin K antagonists: the clinical impact of individual time within target range in patients with heart disease

  2006influential reference
• Worldwide Management of Oral Anticoagulant Therapy: the ISAM Study

  2006cited by this paper
• Monitoring anticoagulation in atrial fibrillation

  2006influential reference
• Effect of study setting on anticoagulation control: a systematic review and metaregression.

  2006influential reference
• Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy.

  2005influential reference
• Cardiovascular magnetic resonance of left ventricular pseudoaneurysm

  2005influential reference
• Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.

  2005cited by this paper
• Antithrombotic therapy practices in US hospitals in an era of practice guidelines.

  2005cited by this paper
• Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population.

  2005cited by this paper
• Systematic overview of warfarin and its drug and food interactions.

  2005cited by this paper
• Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long‐term recurrence

  2005cited by this paper
• The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004influential reference
• Effect of warfarin nonadherence on control of the International Normalized Ratio.

  2004cited by this paper
• Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Time trends in warfarin-associated hemorrhage.

  2004influential reference
• Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial.

  2003cited by this paper
• Incidence and preventability of adverse drug events among older persons in the ambulatory setting.

  2003cited by this paper
• Does negative heparin‐platelet factor 4 enzyme‐linked immunosorbent assay effectively exclude heparin‐induced thrombocytopenia?

  2003cited by this paper
• Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism

  2003cited by this paper
• Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.

  2003influential reference
• Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

  2003cited by this paper
• A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

  2002cited by this paper
• Atrial fibrillation or flutter and stroke: a Danish population‐based study of the effectiveness of oral anticoagulation in clinical practice

  2002cited by this paper
• Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

  2002cited by this paper
• A comparison of rate control and rhythm control in patients with atrial fibrillation.

  2002cited by this paper
• Rate control versus electrical cardioversion for atrial fibrillation: A randomised comparison of two treatment strategies concerning morbidity, mortality, quality of life and cost-benefit - the RACE study design.

  2002cited by this paper
• Oral anticoagulation and risk of death: a medical record linkage study

  2002cited by this paper
• Effect of Regimen Complexity on Patient Satisfaction and Compliance With Warfarin Therapy

  2001cited by this paper
• Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities.

  2000cited by this paper
• Why do patients with atrial fibrillation not receive warfarin?

  2000cited by this paper
• Major thromboembolic complications during oral anticoagulant therapy. Importance of level of anticoagulation

  1999cited by this paper
• [Major thromboembolic complications during oral anticoagulant therapy. Importance of level of anticoagulation].

  1999cited by this paper
• Atrial fibrillation and stroke prevention with warfarin in the long-term care setting.

  1997cited by this paper
• Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

  1996cited by this paper
• Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)

  1996cited by this paper
• The Efficacy and Safety of Oral Anticoagulation in Patients with Cancer

  1995cited by this paper
• Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice?

  1994cited by this paper
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

  1994cited by this paper
• Anticoagulation in Atrial Fibrillation: Does Efficacy in Clinical Trials Translate Into Effectiveness in Practice?

  1994cited by this paper

• Evaluation of Patients Hospitalized Due to Bleeding Complications Associated with Warfarin Treatment

  2025cites this paper
• Analysis of Personalized Cardiovascular Drug Therapy: From Monitoring Technologies to Data Integration and Future Perspectives

  2025cites this paper
• Analytical performance and user-friendliness of four point-of-care measuring systems for monitoring prothrombin time international normalized ratio in the hands of the intended users

  2025cites this paper
• Awareness and Perception of Dentists in Kuwait Regarding the Dental Management of Patients on Oral Antithrombotic Medications

  2023cites this paper
• Long-Term Outcomes of Bariatric Surgery in Patients on Chronic Anticoagulation

  2023cites this paper
• Anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: Arguments for or against

  2023cites this paper
• Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)

  2022cites this paper
• Direct oral anticoagulants versus vitamin K antagonists in epistaxis patients: A systematic review and meta‐analysis

  2021cites this paper
• Dried blood spot self-sampling with automated capillary electrophoresis processing for clinical analysis.

  2020cites this paper
• Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms

  2020cites this paper
• Plasma Metabolites as Predictors of Warfarin Outcome in Atrial Fibrillation

  2019cites this paper
• Effect of warfarin versus aspirin on blood viscosity in cardioembolic stroke with atrial fibrillation: a prospective clinical trial

  2019cites this paper
• Moving anticoagulation initiation and monitoring services into the community: evaluation of the Brighton and hove community pharmacy service

  2018cites this paper
• Anticoagulation therapy: patients attitude, knowledge, and concerns regarding their effects on the international normalized ratio (INR) in Saudi Arabia

  2018cites this paper
• Anticoagulation Therapy: For Patients Attitude, Knowledge and Concerns Regarding their Effects on International Normalized Ratios in Saudi Arabia

  2018cites this paper
• Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study

  2018cites this paper
• Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Retrospective Population Study

  2018cites this paper
• Predictors of Over-Anticoagulation in Warfarin Users in the UK General Population: A Nested Case–Control Study in a Primary Health Care Database

  2018cites this paper
• Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort

  2018cites this paper
• Assessment of the quality of anticoagulation management in patients with pulmonary arterial hypertension.

  2017cites this paper
• Adherence in outpatients taking warfarin and its effect on anticoagulation control in Jordan

  2016cites this paper
• Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge.

  2016cites this paper
• Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation

  2015cites this paper
• Original article Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation

  2015cites this paper
• Clinical effectiveness of INR patient self-testing: Adults on warfarin therapy in private practice

  2015cites this paper
• Plasma transfusion trials and tribulations

  2015cites this paper
• Pharmacovigilance of herb-drug interactions among preoperative patients.

  2014cites this paper
• Personalized anticoagulant management using reinforcement learning.

  2014influential citation
• Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation

  2014cites this paper
• Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.

  2014cites this paper
• Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control.

  2014cites this paper
• Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation

  2014cites this paper
• Can Genetic Testing Improve Outcomes in Patients Who Take Vitamin K Antagonists

  2014cites this paper
• Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.

  2013cites this paper
• 1299-1307 Varad R. Pradhan 347

  2013cites this paper
• Personalised treatment with oral anticoagulant drugs : clinical and economic issues

  2013cites this paper
• Comparison of three medication adherence measures in patients taking warfarin

  2013cites this paper
• A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.

  2013cites this paper
• SIMULTANEOUS LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRIC DETERMINATION OF WARFARIN ENANTIOMERS IN HUMAN PLASMA AND ITS APPLICATION TO A BIO-EQUIVALENCE STUDY IN INDIAN POPULATION

  2013cites this paper
• Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin

  2012cites this paper
• Genetic, clinical and behavioural determinants of vitamin K-antagonist dose--explored through multivariable modelling and visualization.

  2012cites this paper
• Long‐term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users

  2012cites this paper
• PRM26 Comparison of Three Medication Adherence Measures in Patients Taking Warfarin

  2012cites this paper
• Psychometric properties of the 8-item Morisky Medication Adherence Scale in patients taking warfarin

  2012cites this paper
• Determination of free and total warfarin concentrations in plasma using UPLC MS/MS and its application to a patient samples.

  2012cites this paper
• Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study

  2012cites this paper
• POINT-OF-CARE TESTING FOR ORAL ANTICOAGULANT MANAGEMENT WITH PORTABLE PROTHROMBIN TIME SYSTEMS

  2011cites this paper
• Prevalent aetiologies of non‐therapeutic warfarin anticoagulation in a network of pharmacist‐managed anticoagulation clinics

  2011cites this paper
• Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy.

  2010cites this paper
• Improving Anticoagulation Control in Hospitalized Elderly Patients on Warfarin

  2010influential citation
• A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.

  2010cites this paper
• Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.

  2009cites this paper